AI-driven drug discovery has raised roughly $24 billion by mid-2026, but that headline conceals a sharp pattern: a small number of companies and late-stage rounds capture the lion’s share of capital. The distribution matters for how quickly AI techniques will translate into clinically validated medicines. Where the capital is concentrated Funding is heavily skewed toward […]